Intraoperative Placement of Superficial Erector Spinae Plane Block; A New Approach in Spine Surgery

Sponsor
Bakirkoy Dr. Sadi Konuk Research and Training Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05244031
Collaborator
(none)
46
1
2
9
5.1

Study Details

Study Description

Brief Summary

Major spine surgery causes severe postoperative pain. The primary objective of this randomized controlled study is to compare the effect of ultrasound (US)-guided superficial erector spinae plane (ESP) block on 48-hour postoperative cumulative opioid requirements with standard (opioid-based) analgesia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: superficial erector spina plane block
  • Procedure: Standard (opioid-based) analgesia
N/A

Detailed Description

46 patients (ASA I-II-III) between 18 and 65 years of age, who were to undergo spine surgery, were randomized and divided into two groups. (23 patients in each of the control and superficial ESP groups). Superficial ESP block was performed for SESP group and standard (opioid-based) analgesia performed in the control group. Postoperative analgesia was provided by intravenous morphine infusion using a patient-controlled analgesia device. Postoperative numeric rating scale values were the primary outcome measure. 24-hour total morphine consumption was secondary outcome measure.

Study Design

Study Type:
Interventional
Actual Enrollment :
46 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Intraoperative Placement of Superficial Erector Spinae Plane Block in Spine Surgery; An Effective Approach at Enhanced Recovery After Spine Surgery
Actual Study Start Date :
May 10, 2021
Actual Primary Completion Date :
Feb 7, 2022
Actual Study Completion Date :
Feb 7, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Superficial ESP

The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia

Procedure: superficial erector spina plane block
The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia

Active Comparator: Control group

The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia

Procedure: Standard (opioid-based) analgesia
The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia

Outcome Measures

Primary Outcome Measures

  1. NRS scores of patients [48 hours postoperatively]

    NRS at 1, 6,12, 18, 24, 36, 48th hours

Secondary Outcome Measures

  1. Postoperative 48-hours total morphine consumption [48 hours postoperatively]

    This will be measured only one time by pca device at the 48th hour after surgery.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ages of 18-65

  • Patients who will undergo spine surgery (at least two level)

  • ASA I-II-III patients

Exclusion Criteria:
  • Clinically known local anesthetic allergy

  • Morbid obesity (body mass index>40 kg m2)

  • Clinically diagnosis of opioid, alcohol and substance dependence

  • Clinically diagnosis of psychiatric disease

  • Coagulopathy

  • Patients with ASA IV-V

  • Single level surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bakirkoy Dr. Sadi Konuk Research and Training Hospital Istanbul Bakirkoy Turkey 34147

Sponsors and Collaborators

  • Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gokhan Sertcakacilar, MD, Principal investigator, Bakirkoy Dr. Sadi Konuk Research and Training Hospital
ClinicalTrials.gov Identifier:
NCT05244031
Other Study ID Numbers:
  • 2021-271
First Posted:
Feb 17, 2022
Last Update Posted:
Mar 3, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Gokhan Sertcakacilar, MD, Principal investigator, Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2022